FasT CAR-T

This page shows the latest FasT CAR-T news and features for those working in and with pharma, biotech and healthcare.

Gracell Bio developing faster, cheaper CAR-T production

The company's 'FasT CAR-T' only requires eight days to complete the production process, which is made up of the one day of manufacturing plus seven days for releasing tests, ... Without support from patients, their families, and clinical scientists, we

Latest news

Janssen’s CAR-T gains PRIME status in Europe

EMA fast-track could help Janssen close gap. Janssen has been granted a valuable PRIME (Priority Medicines) designation from the European Medicines Agency for its CAR-T candidate for multiple myeloma, ... The CAR-T therapy would complement Janssen's
Gilead strikes deal with NHS England on CAR-T Yescarta

NHS England claims adult leukaemia access is first in Europe. NHS England has agreed a market access deal with Gilead for its groundbreaking CAR-T therapy Yescarta, and is claiming it ... It is likely that we are only beginning to see the benefits that

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

New models of NHS care – new models of pharma response?

Most notably, fast patient access for CAR-T cell therapies, Gilead’s Yescarta and Novartis’ Kymriah, where England has been ahead of its European counterparts in making the drugs available. ... CAR-T therapies are cost-effective for these patients,